Methoxyflurane inhalation - Medical Developments International

Drug Profile

Methoxyflurane inhalation - Medical Developments International

Alternative Names: Green whistle - Medical Developments International; Penthrop; Penthrox

Latest Information Update: 14 Sep 2016

Price : $50

At a glance

  • Originator Medical Developments International
  • Developer LINK Healthcare; Medical Developments International
  • Class Fluorinated hydrocarbons; General anaesthetics; Methyl ethers; Muscle relaxants; Small molecules
  • Mechanism of Action GABA receptor modulators; Gap junction modulators; Glutamate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 11 Sep 2016 Methoxyflurane inhalation licensed to Purdue Pharma for distribution in Canada
  • 25 Sep 2015 Methoxyflurane inhalation licensed to LINK Healthcare for commercialisation in South Africa and Singapore ,
  • 23 Sep 2015 Launched for Pain in Singapore (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top